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Abstract
Background: Chronic obstructive pulmonary disease (COPD) remains a major public health problem that affects
the quality of life of patients, however smoking cessation may emeliorate the functional effects of COPD and alter
patient quality of life.
Objective-design: The aim of this study was to validate the Clinical COPD Questionnaire (CCQ) into Greek and
with such to evaluate the quality of life in patients with different stages of COPD, as also assess their quality of life
before and after smoking cessation.
Results: The internal validity of questionnaire was high (Cronbach’s a = 0.92). The reliability of equivalent types in
16 stabilized patients also was high (ICC = 0.99). In general the domains within the CCQ were strongly correlated
with each other, while each domain in separate was strongly correlated with the overall CCQ score (r
2 = 0.953, r
2 =
0.915 and r
2 = 0.842 in regards to the functional, symptomatic and mental domain, respectively). The CCQ scores
were also correlated with FEV1, (r
2 = -0.252, p < 0.001), FEV1/FVC, (r
2 = -0.135, p < 0.001) as also with the quality of
life questionnaire SF-12 (r
2 = -0.384, p < 0.001). Smoking cessation also lead to a significant reduction in CCQ score
and increase in the SF-12 score.
Conclusions: The self administered CCQ indicates satisfactory validity, reliability and responsiveness and may be
used in clinical practice to assess patient quality of life. Moreover the CCQ indicated the health related quality of
life gains attributable to smoking cessation among COPD patients, projecting smoking cessation as a key target in
COPD patient management.
Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease. Its pulmonary component
is characterized by airflow limitation that is not fully
reversible. This airflow limitation is usually progressive
and associated with an abnormal inflammatory response
of the lung to noxious particles or gases, such as those
emitted during smoking [1]. COPD has considerable
implications on the quality of life of patients and may
overload the health care system and increase health care
expenditure [1,2]. Moreover at a global level, COPD is a
significant public health issue and is the fourth leading
cause of illness and mortality worldwide, while up to the
year 2030 it is expected to be the third largest cause of
death [3-5].
Tobacco smoking continues to be a major cause of
COPD, while passive smoking may also contribute to
respiratory symptoms and COPD progression [4,6,7].
C i g a r e t t es m o k e r sh a v eah i g h e rp r e v a l e n c eo fr e s p i r a -
tory symptoms and lung function abnormalities, while
on the contrary, smoking cessation has been found to
reduce the rapid decline in FEV1 [8]. Smoking cessation
i st h es i n g l em o s te f f e c t i v e –and cost effective–way to
reduce the possibility of developing COPD as smoking
cessation can prevent or delay the development of air-
flow limitation, or reduce its progression [9]. With the
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smoking is a primary tool within the ideal management
of COPD. Moreover, the Initiative for Chronic Obstruc-
tive Lung Disease includes goals related to clinical (pre-
vention of disease progression and minimization of
symptoms) and health-related quality of life (improved
exercise tolerance and emotional function) among
COPD patients indicating the interaction between
respiratory illness and quality of life [10]. Health status,
functional status, and quality of life are three concepts
often used interchangeably to refer to this same domain
of health. Indeed, Health-Related Quality of Life
(HRQL) is important for measuring the impact of
chronic disease such as COPD. With the above initiative
in mind, the necessity to develop new questionnaires
that assess quality of life within COPD patients was
emphasized so as to help determine and treat functional
problems which are important in patients with COPD
[11,12]. However as the tool must be easy to use in clin-
ical practice as also evaluate symptoms and the func-
tional and intellectual situation of patients, the Clinical
COPD Questionnaire (CCQ) was developed [13]. With
the above in mind the aim of the present study was to i)
assess the CCQ’s validity among both healthy adults and
patients with COPD, ii) to assess the test-retest reliabil-
ity of the CCQ and iii) to assess quality of life among
COPD patients before and after smoking cessation.
Methods
Subjects
Three study populations were recruited so as to evaluate
the three separate objectives as depicted in the flowchart
of Figure 1. All subjects visited the 10
th outpatient pul-
monary clinic of the Sotiria hospital in Athens after a
scheduled appointment. So as to assess the internal valid-
ity and consistency of the CCQ we enrolled 148 subjects
(102 men and 46 women), of these 93 had COPD (67 men
and 26 women, aged from 41-90 years) and 55 were
healthy participants (36 men and 19 women, aged from
41-60 years old). Healthy subjects were hospital staff while
none of these controls reported current respiratory symp-
toms (cough or dyspnoia). All recruited patients with
COPD were stabilized and had a history of smoking >12
pack/years. We excluded COPD patients with: 1) signifi-
cant improvement of FEV1 >15% and/or 200 ml compared
with baseline (it is diagnostic for bronchial asthma), 2)
asthma, chronic heart failure, obstructive sleep apnoea
syndrome, cancer or other disabling diseases except
COPD, 3) disease exacerbation in the previous four weeks
4) significant self reported shortness of breath in the past
4 days, 5) patients under 40 years of age.
According to the guidelines, COPD was defined by the
presence of chronic cough, sputum production and/or
dyspnoea and subsequently categorised as either mild,
moderate, severe or very severe [10]. According to their
Figure 1 Flowchart of participant followup.
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gorized as: Stage I Mild COPD: 22 patients, 17 men
(18.2%) and 5 women (5.37%), Stage-II Moderate
C O P D :6 5p a t i e n t s ,4 6m e n( 4 9 . 4 % )a n d1 9w o m e n
(20.4%), Stage III Severe COPD: 6 patients, 4 men
(54.3%) and 2 women (2.15%). Table 1 depicts the char-
acteristics of the study population.
Lung function testing
All subjects individually, gave their written informed
consent for baseline spirometry and before the adminis-
tration of the questionnaire, as approved by the Medical
Ethics Committee of the University of Athens.
Lung function (using FEV1 and FVC) was measured
according to ERS guidelines with the use of wedge
spirometry (ZAN 300 CO diffusion), in base condition
in all subjects and 15 minutes metered inhalation of
400 mcg of salbutamol, only in patients with COPD.
Spirometry was undertaken on all patients to make a
confident diagnosis of COPD and to exclude other diag-
noses that may present similar symptoms. Spirometry
measurements were evaluated by comparison with refer-
ence values based on age, height, sex, and race [14,15].
Questionnaire selection and procedures
The subjects were requested to complete the Greek ver-
sion of the SF-12v2 (Short Form Health Survey SF-
12v2) and the clinical COPD questionnaire (CCQ) [16]
(Table 2). Permissi o nf o ru s ew a so b t a i n e df r o mT .v a n
der Molen (2005), who provided the research team with
a translated-back translated version of the CCQ in
Greek. Participants completed the questionnaire set in a
random order to avoid bias. The administrator used a
standardized script to explain the requirements of the
questionnaires, and any questions were answered.
Test-retest reliability was estimated in a second sub-
group of 16 stabilized COPD patients, with the CCQ
administered at two separate occasions with a difference
of 5 days. Responsiveness of the CCQ after smoking ces-
sation, was examined among a third group of 26
patients (16 men and 10 women) who were while re-
administered the CCQ and SF-12v2 after a period of
two months after they were counseled to stop smoking
and successfully quit (without them taking any medica-
tion or therapy to quit).
The CCQ is a very short 10 question survey through
which patients are requested to recall their experiences
during the previous week in regards to their symptoms,
functional and mental state. It is self-administered and
takes patients approximately 2 minutes to complete. It
is subdivided into three domains: symptom related
(items 1-2-5-6), functional state related (items 7-8-9-10)
and mental state related (items 3-4). Subjects respond to
each question on a 7 point scale (ranging between 0 =
asymptomatic/no-limitation, to 6 = extremely sympto-
matic/totally limited). The overall clinical COPD control
score and the score of the three domains is calculated
by adding all the scores together and dividing the sum
by the number of questions.
Statistical analysis
The descriptive data is presented as mean ± standard
deviation for continuous variables and in percentages
(n) for categorical. The internal consistency of the CCQ
questionnaire was evaluated with the use of the Cron-
bach’s alpha test while the test retest reliability of the
CCQ questionnaire was assessed with the use of the
interclass correlation coefficient. During the comparison
of the CCQ score before and after smoking cessation, all
pairs of questions (before and after smoking cessation)
as well as the total score (before and after smoking ces-
sation) were assessed with the use of non parametric
tests, as the data was skewed. All reported analyses are
based on two sided tests, while statistical significance
Table 1 Descriptive statistics of the study population
COPD group
Control group
(n = 55)
All stages of COPD
(n = 93)
Stage I: Mild COPD
(n = 22)
Stage II: Moderate COPD
(n = 65)
Stage III: Severe COPD
(n = 6)
% (n) % (n) % (n) % (n) % (n)
Gender(male) 63.6% (35) 72% (67) 81.8% (18) 69.2% (45) 66.7% (4)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (mean) 60.45 ± 11.46 66.35 ± 9.68 55.14 ± 7.03 68.80 ± 6.57 81 ± 8.65
CCQ Total Score 0.05 ± 0.11 1.437 ± 1.19 1.09 ± 1.17 1.58 ± 1.19 1.17 ± 1.20
CCQ Symptoms 0.05 ± 0.19 1.357 ± 1.16 1.15 ± 1.07 1.44 ± 1.20 1.25 ± 1.20
CCQ Functional state 0.05 ± 0.10 1.720 ± 1.49 1.25 ± 1.47 1.92 ± 1.48 1.25 ± 1.46
CCQ Mental state 0.05 ± 0.16 1.032 ± 1.18 0.66 ± 1.24 1.18 ± 1.17 0.83 ± 0.88
FEV1 97.65 ± 8.70 70.06 ± 11.1 82.66 ± 2.95 67.94 ± 7.99 46.83 ± 3.93
FEV1/FVC 89.42 ± 7.85 62.90 ± 7.7 69.43 ± 2.17 60.75 ± 7.75 62.27 ± 7.63
SF-12 3.10 ± 0.33 2.909 ± 0.36 3.14 ± 0.33 2.87 ± 0.33 2.49 ± 0.26
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ent questionnaires were performed and the R
2 values
were also noted. The statistical package SPSS 18.0 was
used to perform the analysis.
Results
Internal consistency of the CCQ
The Cronbach’s alpha for the Greek CCQ, was calculated
at 0.929 for the patients with COPD (n = 93), and similarly
in both men (n = 67) and women (n = 26), with a value of
0.932 and 0.926 respectively. Among the entire population,
Cronbach’s a, was calculated at 0.943 (n = 148).
Test-retest reliability
Test-retest reliability was estimated twice, in a separate
population of 16 stable patients so as to assess the inter-
class correlation coefficient (ICC). The questionnaire
was administered to the patients for the first time (t1)
during their initial visit. A repeat administration (t2)
after 5 days was chosen, in order to minimize clinical or
Table 2 The Greek version of the Clinical COPD Questionnaire
ΚΛΙΝΙΚΟ ΕΡΩΤΗΜΑΤΟΛΟΓΙΟ ΓΙΑ ΤΗΝ Χ.Α.Π.
Πaraalούμε bάlτε sε ύlο τον arιθμό τhς aπάντhshς που πεrιgrάει alύτεra το πώς νιώθaτε aτά τhντ ε lευτaίa εbδομάδa.
(μόνομ ί aa πάντhsh gιa άθε εrώτhsh)
Κaτάμ έ sοό rο, aτά τhν
τεlευτaίa εbδομάδa, πόsο
sυcνά νιώsaτε:
Ποτέ Σcεδόν ποτέΜ εrιές οrές Αrετές οrές Ποllές οrές Πάra ποllές
οrές
Σcεδόν
sυνέcειa
1. Λacάνιasμa ότaν
ήsasτε sε aνάπaυsh;
0123456
2. Λacάνιasμa ότaν
είcaτε sωμaτιές
δrasτhrιότhτες;
0123456
3. Ανήsυcος/h μήπως
οllήsετε άποιο
rυοlόghμa ή μήπως
cειrοτεrέψει ha νaπνοή
saς;
0123456
4. Θlιμμένος/h
(lυπhμένος/h) lόgω των
aνaπνευsτιών saς
πrοblhμάτων;
Γενιά aτά τhντ ε lευτaίa
εbδομάδa, πόsο aπό τον
crόνο:
0123456
5. Βήcaτε; 0123456
6. Είcaτε lέμaτa;
Κaτάμ έ sοό rο, aτά τhν
τεlευτaίa εbδομάδa,
πόsοπ εrιοrιsτήaτε sτις
πaraάτω δrasτhrιότhτες
lόgω των aνaπνευsτιών
saςπ rοblhμάτων;
0 Δεν
πεrιοrίsτha
aθόlου
1
Πεrιοrίsτha
ποlύ lίgο
2
Πεrιοrίsτha
lίgο
3
Πεrιοrίsτha
μέτrιa
4
Πεrιοrίsτha
ποlύ
5
Πεrιοrίsτha
πάra ποlύ
6
Πεrιοrίsτha
τεlείωςή
aνίaνος νa
τις άνω
7. Εντaτιές sωμaτιές
δrasτhrιότhτες (όπως το
νaa νεbaίνετε sάlες, το
νab ιάζεsτε, το νa άνετε
aθlhτιsμό);
0123456
8. Μέτrιες sωμaτιές
δrasτhrιότhτες (όπως
πεrπάτhμa, νοιουrιό,
μετaοrάπ ragμάτων);
0123456
9. Κaθhμεrινές
δrasτhrιότhτες sτο sπίτι
(όπως το νa ντύνεsτε,
πlένεsτε);
0123456
10. Κοινωνιές
δrasτhrιότhτες (όπως το
νa μιlάτε, το νa είsτε με
πaιδιά, ή το νa
επιsέπτεsτε ίlους/
sυggενείς);
0123456
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of previous answers. The mean of ICC value of the total
CCQ score was 0.990 (0.971 - 0.996). The scores are
showed in Table 3, indicating the test-retest reliability of
the CCQ in Greek.
Convergent and divergent validity
In general the domains within the CCQ were strongly cor-
related with each other, while each domain in separate was
strongly correlated with the overall CCQ score (r
2 = 0.953,
r
2 =0 . 9 1 5a n dr
2 = 0.842 in regards to the functional,
symptomatic and mental domain, respectively). The CCQ
scores were also correlated with FEV1, (r
2 = -0.252,
p < 0.001), FEV1/FVC, (r
2 = -0.135, p < 0.001) as also with
the quality of life questionnaire SF-12 (r
2 = -0.384, p <
0.001) (Table 4). A statistically significant decrease in
breath function tests (FEV1, FEV1/FVC), and the SF-12
score were noted when the CCQ score increased indicating
the construct validity and the external criterion related
validity respectively.
Smoking cessation: Sensitivity-responsiveness of the CCQ
and quality of life
Sensitivity responsiveness was examined in a separate
population of 26 patients with COPD (16 men and 10
women, with a median age of 66.5 years (range 45-88),
that smoked and were recommended to quit smoking.
Among these patients that had successfully quit smoking
after 2 months, the CCQ was re-administered. The CCQ
scores significantly improved after two months of smoking
cessation in patients with COPD. Specifically there was a
statistically significant decrease in the frequency of devel-
oping shortness of breath during physical activities (p =
0.008), in the appearance of cough (p = 0.002) and phlegm
(p = 0.008) as also among daily activities at home
(p = 0.034). Strenuous physical activity and moderate phy-
sical activity were not affected among these patients. It is
interesting to note that the frequency of reporting ever
being “concerned about getting a cold or your breathing
getting worse” as also feeling “depressed because of your
breathing problems” was found to decrease statistically sig-
nificantly after smoking cessation (p = 0.005 and p = 0.011
respectively), as depicted in Table 5.
This subgroup of 26 patients with COPD that success-
fully quit smoking and remained non smokers 2 months
after the initial contact also completed the Greek ver-
sion of the SF-12v2 (before and after two months smok-
ing cessation) through which significant differences in
quality of life was noted for all domains (p < 0.05 in all
cases) indicating the usefulness of smoking cessation in
improving quality of life among COPD patients.
Discussion
Main findings
Within the context of this study, smoking cessation
among COPD patients was shown to lead within
2 months to an increase in the rated quality of life in a
significant number of health domains, as examined with
the use of the clinical COPD questionnaire (CCQ) and
the SF12. Moreover the CCQ, was identified as a sensi-
tive and useful tool for asses s i n gq u a l i t yo fl i f ea m o n g
COPD patients.
In regards to the Greek translation, the internal valid-
ity of the applied questionnaire was high among both
patients with COPD and healthy volunteers, while the
elevated correlations between the CCQ’sd o m a i n si n d i -
cate a homogenized questionnaire. In comparison to the
Dutch, Italian and Swedish versions of the current
Table 3 Test re-test reliability of the CCQ taken with a 5 days difference among patients with COPD as indicated
through the Inter Correlation Coefficient (ICC) (n = 16)
95% C.I
ICC Lower Limit Upper Limit
CCQ total score before - CCQ total score after 0.990 0.971 0.996
On average, during the past 24 hours, how often did you feel:
Short breath at rest? 0.977 0.935 0.992
Short of breath doing physical activities? 0.979 0.941 0.993
Concerned about getting a cold or your breathing getting worse? 0.920 0.788 0.971
Depressed (down) because of your breathing problems? 0.967 0.908 0.988
In general, during the past 24 hours, how much of the time:
Did you cough? 0.990 0.972 0.997
Did you produce phlegm? 0.939 0.836 0.978
On average, during the past 24 hours, how limited were you in these activities because of your breathing problems:
Strenuous physical activities 0.976 0.933 0.992
Moderate physical activities 0.983 0.952 0.994
Daily activities at home 0.948 0.859 0.982
Social activities 0.976 0.932 0.991
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indicating its successful translation from English. (T.Van
der Molen 2003: a = 0.91, Salvatore Damato 2005: a =
0.89, Björn Ställberg 2009: a = 0.82) [13,17,18].
Chronic obstructive pulmonary disease is a major cause
of morbidity and mortality worldwide [1,2]. Among
patients with COPD the goals of clinical control include:
improved exercise tolerance, emotional function, preven-
tion of disease progression and minimization of symp-
toms, all of which may lead to an increased quality of life
[10]. Quality of life is an important factor in patient treat-
ment and its scientific documentation is a necessity in
clinical practice, for instance HRQL in patients with
COPD is related to impaired FEV1 [19]. With this in
mind, the CCQ as seen through the context of this study,
can pick up the differences noted between each state of
COPD and thus help categorize each patient and assess
their symptomatic, mental and functional status, with the
latter found to be related to the clinical outcome of lung
function tests. In general patients with mild COPD have
better respiratory function test (FEV1,F E V 1/FVC) than
patients with moderate COPD, and this association was
also indicated through our study [20,21].
Among the factors that are leading causes of COPD
is tobacco smoking [2,3,8 ]. It causes airflow limitation
which is slowly progressive and irreversible. Persistent
smoking is associated with rapid longitudinal decline
in FEV1 and poor prognosis, indicating that [1,4,8,9],
smoking cessation is an effective way to reduce the
progress of the disease as also the likelihood of actually
developing COPD [4,8,9,22]. Smoking cessation leads
to prolonged improvements in endothelial function
[23] and also associated with substantially improved
cardiovascular function and reduced risk of primary
and secondary cardiovascular morbidity and mortality
[24]. Chronic exposure to cigarette smoke causes
increased production of metalloproteinases by macro-
phages and proteolitic enzymes by neutrophils [25]
and decrease in pulmonary mature dendritic cells [26].
Moreover, tobacco smoke compromises the anti-bac-
terial function of leukocytes, including neutrophils,
monocytes, T cells and B cells, providing a mechanistic
Table 5 Comparison between the CCQ scores before and after smoking cessation among COPD patients (n = 26)
Before After
N Mean ± SD Mean ± SD p-value
1 ICC 95% C.I
CCQ total scores before and after 26 1.08 ± 0.82 0.72 ± 0.69 <0.001 0.848 0.690 - 0.929
On average, during the past 24 hours, how often did you feel:
Short breath at rest 26 0.50 ± 0.86 0.19 ± 0.49 0.054 0.367 -0.016 - 0.656
Short of breath doing physical activities? 26 0.88 ± 1.10 0.50 ± 0.86 0.008 0.793 0.591 - 0.902
Concerned about getting a cold or your breathing getting worse? 26 0.88 ± 1.21 0.30 ± 0.73 0.005 0.595 0.276 - 0.795
Depressed (down) because of your breathing problems? 26 0.65 ± 1.01 0.34 ± 0.79 0.011 0.820 0.638 - 0.915
In general, during the past 24 hours, how much of the time:
Did you cough? 26 1.65 ± 1.44 1.00 ± 1.23 0.002 0.734 0.491 - 0.871
Did you produce phlegm? 26 1.38 ± 1.09 0.92 ± 0.89 0.008 0.711 0.452 - 0.859
On average, during the past 24 hours, how limited were you in these activities because of your breathing problems:
Strenuous physical activities 26 2.53 ± 1.88 2.19 ± 1.38 0.083 0.825 0.648 - 0.918
Moderate physical activities 26 1.46 ± 1.83 1.19 ± 1.60 0.161 0.844 0.683 - 0.927
Daily activities at home 26 0.61 ± 1.09 0.38 ± 0.94 0.034 0.874 0.738 - 0.941
Social activities 26 0.23 ± 0.58 0.19 ± 0.56 0.317 0.942 0.876 - 0.974
1: Non parametric tests were applied.
Table 4 Correlations between questionnaire responses, quality of life and respiratory function in patients with COPD
(N = 93)
CCQ Total CCQ Symptoms CCQ Function CCQ Mental FEV1 FEV1/FVC SF
CCQ Total 1 0.915** 0.953** 0.842** -0.252* -0.135 -0.384**
CCQ Symptoms 0.915** 1 0.779** 0.685** -0.230* -0.100 -0.292**
CCQ Function 0.953** 0.779** 1 0.754** -0.260 -0.145 -0.435**
CCQ Mental 0.842** 0.685** 0.754** 1 -0.164 -0.116 -0.267**
FEV1 -0.252* -0.230* -0.260* -0.164 1 0.358** 0.538**
FEV1/FVC -0.135 -0.100 -0.145 -0.116 0.358** 1 0.345**
SF -0.384** -0.292** -0.435** -0.267** 0.538** 0.345** 1
* indicates a statistically significant association of p < 0.05.
** indicates a statistically significant association of p < 0.001.
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have an effect on health outcomes [27]. Indeed,
patients with COPD have an increased risk of mortality
compared to those who do not, with consequent
reduction in life expectancy [28]. Smoking cessation
can improve the symptoms that COPD patients often
experience (such as dyspnoia and cough) as also indi-
cated among the patients of our study, through which
smoking cessation led to a statistically significant
r e d u c t i o ni nC O P Ds y m p t o m ss u c ha sc o u g ha n dd y s -
pnoia as also an increased physical endurance (such as
walking up a flight of stairs) with significant clinical
implications for patient outcome.
Strengths and limitations
The aim of the current study was to assess the change
in HRQL among COPD patients before and after smok-
ing cessation, as also to assess the validity and applic-
ability of the CCQ, therefore we did not investigate into
how the 26 COPD patients quit, which was not within
the scope of the study and therefore we were not able
to assess a success rate in smoking cessation. Among
the COPD patients that quit smoking during the dura-
tion of the study, respiratory assessment was not avail-
able during the post cessation assessment and therefore
we were unable to assess the role of smoking cessation
on respiratory function with clinical observations, how-
ever such scientific evidence is already well known
[9,22]. Moreover the sample size could have been even
larger for a complete validation study and we must note
that during the analysis we classified three groups of
patients with COPD, out of which the sample of
patients with severe COPD was low (n = 6) and there-
fore the results might not be indicative of patients with
s e v e r eC O P D ,a st h i ss m a l ln u m b e ro fp a t i e n t sw e r e
relatively more healthy in comparison to the patients
(n = 65) with mild COPD. Furthermore, we did not
examine patients with very severe COPD and these fac-
tors should be taken into account in future studies.
Conclusions
The clinical COPD questionnaire is the first to have
been specifically developed and validated to measure
control in patients with COPD. The validation of the
questionnaire in Greek and in specific clinical pulmon-
ary disease practice, confirms strong discriminative
properties, test-retest reliability and responsiveness.
Applying the CCQ within the context of this study,
smoking cessation was related to improved HRQL
scores, and a reduction in COPD related symptoms,
indicating the necessity for active interventions by health
professionals to help COPD patients quit smoking as a
primary tool for the adequate management of COPD
and the patient’s quality of life.
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